Hillsdale Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Hillsdale Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.82M	Buy	468,000 +32,490	+7%	+$437K	0.16%	182
2026 Q1	$5.5M	Buy	435,510 +13,210	+3%	+$177K	0.15%	167
2025 Q4	$6.66M	Buy	+422,300	New	+$5.36M	0.18%	141
2023 Q1	–	Sell	-53,300	Closed	-$2.48M	–	592
2022 Q4	$2.48M	Hold	53,300	–	–	0.21%	150
2022 Q3	$2.76M	Hold	53,300	–	–	0.25%	142
2022 Q2	$2.52M	Hold	53,300	–	–	0.2%	153
2022 Q1	$3.79M	Sell	53,300 -650	-1%	-$42.3K	0.25%	140
2021 Q4	$4.04M	Buy	+53,950	New	+$4.23M	0.27%	127

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Hillsdale Investment Management's ENTA Position: Q2 2026 in Review

Hillsdale Investment Management increased its Enanta Pharmaceuticals (ENTA) stake by 7.5% in Q2 2026, buying an estimated $437K and bringing the position to 468,000 shares worth $6.82M. The position accounts for 0.16% of the portfolio, ranked #182.

Hillsdale Investment Management first reported a position in ENTA in Q4 2021 and has held it in 8 quarters since. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Hillsdale Investment Management held 468,000 shares of Enanta Pharmaceuticals worth $6.82M as of Q2 2026.
Hillsdale Investment Management bought 32,490 Enanta Pharmaceuticals shares in Q2 2026, an estimated $437K.
Enanta Pharmaceuticals made up 0.16% of Hillsdale Investment Management's portfolio in Q2 2026, its #182 holding.
Hillsdale Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.